Search Results
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Ligand Pharmaceuticals
Jul 10, 2024, 05:18 |
Insight
APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million
APEIRON Biologics AG (“APEIRON”), a leading Austrian biotech company, today announced that its shareholders have…
May 13, 2024, 07:25 |
Blog
Partnership between Ligand Pharmaceuticals and Agenus
Ligand Pharmaceuticals shared on their LinkedIn page: "We are excited to announce our latest royalty…
May 12, 2024, 03:08 |
Blog
CEO of Agenus, Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals
Agenus shared on LinkedIn: “‘With this infusion of capital, we are poised to accelerate the…
May 9, 2024, 12:46 |
Blog
Zack Armen: A major transaction with Ligand Pharmaceuticals and Agenus
Zack Armen, Head of Investor Relations at Agenus, shared a post on LinkedIn: ''Yesterday we…
May 24, 2024, 01:22 |
Blog
Tanja Obradovic on Radiopharmaceuticals in oncology
Tanja Obradovic shared a post on LinkedIn: "Radiopharmaceuticals in oncology have been recently very active clinical…
Jul 1, 2024, 13:53 |
Drugs
Todd Davis: Approval of Verona Pharma’s Ohtuvayre
Todd Davis, CEO at Ligand Pharmaceuticals, shared on LinkedIn: "When I stepped in as CEO…
May 16, 2024, 16:51 |
Insight
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
In the fast-growing field of oncology, we are witnessing significant advances in several treatment modalities…
Dec 10, 2023, 17:32 |
Blog
Wafik S. El-Deiry: I wore my chemistry tie today in honor of your visit to Providence and Brown University
Wafik S. El-Deiry, the Director of the Legorreta Cancer Center of Brown University, posted on LinkedIn:…
All:
8
Posts:
1 - 10
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
EMA Joins FDA: Osimerintib + Chemo Approved for EGFR-Mutated Lung Cancer
Kimryn Rathmell: Principles that have kept me going as a Physician Scientist
Facebook
RSS Feed
Twitter
Linkedin
Youtube